CERo Therapeutics Holdings, Inc. (CERO)

OQB – Real vaqt narxi. Valyuta: USD

0.03

-0.00 (-12.90%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

14.04.2026

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)

30.03.2026

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF).

11.03.2026

CERo Therapeutics Provides Shareholder Update

Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum

17.02.2026

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors.

04.02.2026

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a presentation highlighting data to date from the Company's Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236.

07.01.2026

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity (DLT) observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis

14.04.2026

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)

30.03.2026

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

11.03.2026

CERo Therapeutics Holdings, Inc. (CERO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CERo Therapeutics Holdings, Inc. (CERO)

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Videolar

No Data

Press-relizlar

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Videolar

No Data

Press-relizlar

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

Search stocks

CERo Therapeutics Holdings, Inc. (CERO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CERo Therapeutics Holdings, Inc. (CERO)

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Videolar

No Data

Press-relizlar

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Videolar

No Data

Press-relizlar

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update